Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 39 Carcinoma, Non-Small-Cell Lung 30 Esophageal Squamous Cell Carcinoma 22 Carcinoma, Hepatocellular 21 Triple Negative Breast Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 17 Breast Neoplasms 17 Advanced Solid Tumor 17 Stomach Neoplasms 14 Melanoma 14 Small Cell Lung Carcinoma 13 Colorectal Neoplasms 13 Uterine Cervical Neoplasms 12 Neoplasms 10 Carcinoma, Transitional Cell 10 Carcinoma, Renal Cell 10 Recurrence 9 Solid Tumor 7 Sarcoma 7 Neoplasm Metastasis 7 Liver Neoplasms 7 Head and Neck Neoplasms 7 Urinary Bladder Neoplasms 5 Rectal Neoplasms 5 Esophageal Neoplasms 5 Advanced Solid Tumors 5 Pancreatic Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4 Cholangiocarcinoma 4

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × toripalimab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡